Oncolyze Announces FDA Orphan Drug Designation for OM-301 for the Treatment of Acute Myeloid Leukemia
January 05, 2022 09:00 ET
|
Oncolyze Inc
NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Oncolyze, Inc, a biotech developing a disruptive technology for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA)...
IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant
December 16, 2021 07:00 ET
|
IN8bio, Inc
The ongoing Phase 1 trial of INB-100 is the first and most clinically advanced program administering large systemic doses of allogeneic gamma-delta T cells to patients 3 patients have been treated to...
Global Acute Lymphoblastic Leukemia Treatment Market Report 2021-2026: Opportunities with Limited Players in the Market & Increasing Investment in R&D of Different Leukemia Treatments
December 14, 2021 05:48 ET
|
Research and Markets
Dublin, Dec. 14, 2021 (GLOBE NEWSWIRE) -- The "Global Acute Lymphoblastic Leukemia Treatment Market (2021-2026) by Type, Types of Cell, Therapy, Geography, Competitive Analysis and the Impact of...
Tyrokinse Kinase Inhibitors in the Global Oncology Market 2021: Market Leaders by Indication and Product
November 05, 2021 05:58 ET
|
Research and Markets
Dublin, Nov. 05, 2021 (GLOBE NEWSWIRE) -- The "Oncology Markets for Tyrokinse Kinase Inhibitors" report has been added to ResearchAndMarkets.com's offering. Traditional cancer therapy has focused...
Starton Therapeutics Announces Notice of Allowance for U.S. Patent Application Protecting Continuous Delivery of Lenalidomide and Other Immunomodulatory Agents
October 04, 2021 07:00 ET
|
Starton Therapeutics, Inc.
PARAMUS, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc., a clinical stage biotechnology company transforming standard of care therapies with proprietary dermal technologies, today...
AB Science a reçu l’approbation de l’autorité de santé canadienne pour initier une étude de Phase I/II avec sa molécule AB8939 dans le traitement de la leucémie myéloïde aiguë (LMA)
September 22, 2021 12:09 ET
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE A RECU L’APPROBATION DE L’AUTORITE DE SANTÉ CANADIENNE POUR INITIER UNE ÉTUDE DE PHASE I/II AVEC SA MOLÉCULE AB8939 DANS LE TRAITEMENT DE LA LEUCÉMIE MYÉLOÏDE AIGUË...
AB Science receives Health Canada approval letter to commence Phase I/II trial of AB8939 in the treatment of Acute Myeloid Leukemia (AML)
September 22, 2021 12:09 ET
|
AB Science
PRESS RELEASE AB SCIENCE RECEIVES HEALTH CANADA APPROVAL LETTER TO COMMENCE PHASE I/II TRIAL OF AB8939 IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) AB8939 IS A NEW GENERATION SYNTHETIC...
Telix’s TLX66 in Phase II Academic Study of Pediatric Leukemia
August 16, 2021 19:55 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and LONDON , Aug. 17, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the London-based Great Ormond Street Hospital...
Global Chronic Lymphocytic Leukemia (CLL) Disorder Clinical Market Report 2021-2027
July 06, 2021 08:08 ET
|
Research and Markets
Dublin, July 06, 2021 (GLOBE NEWSWIRE) -- The "Chronic Lymphocytic Leukemia (CLL)" report has been added to ResearchAndMarkets.com's offering. Chronic lymphocytic leukemia (CLL) is a disorder where...
Auris Medical Announces Significant Inhibition of Tumor Growth with OligoPhore siRNA Targeting NF-κB in Murine Model of Adult T-Cell Leukemia / Lymphoma
June 21, 2021 08:30 ET
|
Auris Medical AG
Treatment with OligoPhoreTM siRNA stops aggressive ATLL tumor growth to near zeroSignificant reduction in tumor size, spleen size and peripheral blood lymphocyte countsResults add to extensive body of...